(Q45414326)

14 December 2017

title

A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved? (English)

1 reference

14 December 2017

3

Gianpaolo Donzelli

1 reference

14 December 2017

author name string

Maria Serenella Pignotti

series ordinal

1

1 reference

14 December 2017

Serena Catarzi

series ordinal

2

1 reference

14 December 2017

publication date

1 April 2006

1 reference

Journal of Maternal-Fetal and Neonatal Medicine

14 December 2017

published in

1 reference

14 December 2017

volume

19

1 reference

14 December 2017

issue

4

1 reference

14 December 2017

page(s)

221-224

1 reference

Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14767050600591290

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14767050600591290

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14767050600591290

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14767050600591290

Factors impacting compliance with palivizumab prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14767050600591290

10.1080/14767050600591290

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference